• 
• 
• 

• 
• 

Amgen, Inc.

Date Filed: June 5, 2007

Court: U.S. District Court

Location: Central District of California

Ticker Symbol: AMGN

Hagens Berman Sobol Shapiro has filed a proposed nationwide class-action lawsuit against drug manufacturer Amgen, Inc. (NASDAQ:AMGN) alleging the company acted unlawfully in the off-label and deceptive marketing of its drug products known as erythropoiesis-stimulating agents (ESA) drugs, under brand names Epogen and Aranesp.

According to the filed complaint Epogen and Aranesp are approved for use with kidney and cancer patients to boost hemoglobin levels and prevent patients from needing a blood transfusion.

The lawsuit was filed on behalf of patients who have paid for these drugs where the defendant allegedly marketed the products outside of the bounds of their FDA approvals. According to the complaint as a result of these practices the plaintiff paid for ESAs when they would not have otherwise done so.

If you or anyone you know has been taking Epogen or Aranesp please click here to see if you qualify to join the class.

Hagens Berman Sobol Shapiro will keep all information received as confidential and will not share it with third parties.

You can also send us an e-mail at info@hbsslaw.com.

---

RECENT DEVELOPMENTS:

June 10, 2008 - Hagens Berman has been appointed co-lead counsel in the Epogen and Amgen off-label marketing litigation case. The firm is representing a class of consumers and third-party payors who paid for dangerous off-label uses wrongfully promoted by Amgen.

The lawsuit claims prescription dosages used beyond FDA approval were sold to patients with anemia of cancer as well as dialysis patients. Recently, the Center for Medical Services has refused to reimburse for such uses and the FDA has mandated added warnings regarding such uses.

The case is pending in U.S. District Court in Los Angeles. HBSS attorneys on the case include Steve Berman and Rob Lopez.